...
机译:P1.03-013监测晚期ALK阳性非小细胞肺癌(NSCLC)患者的ALK融合和突变
Medical Oncology Department;
Medical Oncology Department;
Drug Development Department;
Exosome Diagnostics GmbH;
Exosome Diagnostics GmbH;
Medical Oncology;
Translational Research Laboratory;
H?pital Georges Pompidou;
Exosome Diagnostics GmbH;
Exosome Diagnostics GmbH;
Exosome Diagnostics Inc;
Drug Development Department;
Radiology Department;
Department of Medical Biology and Pathology Gustave Roussy Cancer Campus;
Translational Research Laboratory;
Department of Medical Biology and Pathology Gustave Roussy Cancer Campus;
Inserm U981 Laboratory;
Drug Development Department;
Medical Oncology Department;
机译:P1.03-013监测晚期ALK阳性非小细胞肺癌(NSCLC)患者的ALK融合和突变
机译:在非小细胞肺癌(NSCLC)中鉴定新型HIP1-ALK融合变体,并在两名对Alectinib产生耐药性的ALK重排NSCLC患者中发现ALK I1171(I1171N / S)突变。
机译:ALK阳性非小细胞肺癌(NSCLC)患者的临床结果(NSCLC)患者DE Novo EGFR或KRAS共突变接受酪氨酸激酶抑制剂(TKIS)Sabine Schmid,Oliver Gautschi,Saha Rothschild,^ Z> Michael Mark,Patrizia Frosech, Dirk Klingbiel,Hermann Reichegger,Wolfram Jochum,Joachim Diebold,Martin Fruh,
机译:使用有效的体内技术(Gilupi Cellcollector
机译:ALK和FLT3激酶抑制剂对非小细胞肺癌细胞和急性髓系白血病细胞的癌症驱动突变的药理作用
机译:非小细胞肺癌(NSCLC)脑转移患者的P08.20EGFR突变状态和EML4融合及回顾性研究
机译:非小细胞肺癌(NSCLC)的新型HIP1-ALK融合变体的鉴定和两名对伊莱替尼耐药的ALK重排NSCLC患者中ALK I1171(I1171N / S)突变的发现